Literature DB >> 19518054

Characterization of protein impurities and site-specific modifications using peptide mapping with liquid chromatography and data independent acquisition mass spectrometry.

Hongwei Xie1, Martin Gilar, John C Gebler.   

Abstract

Liquid chromatography (LC)-based peptide mapping is extensively used for establishing protein identity, assessing purity, and detecting post-translational modifications (PTMs) of recombinant proteins in the biopharmaceutical industry. However, current LC-UV/MS peptide mapping methods require multiple analyses and MS/MS experiments to identify protein contaminants and site-specific PTMs. This manuscript evaluated an alternative approach for protein characterization via peptide mapping employing a data independent LC-MS acquisition strategy with an alternate low and elevated collision energy scanning. The acquired peptide precursor and fragment information was utilized for effective identification of peptide sequences and site-specific modifications within a single LC run. The peptide MS signal intensities were reliably measured and used to estimate relative concentrations of PTMs and/or proteins contaminating the target protein. The method was evaluated using tryptic digests of yeast enolase and alcohol dehydrogenase. LC-eluted peptides were successfully sequenced and covered 97% target protein sequences. Protein impurities and site-specific modifications (e.g., M-oxidation and N-deamidation) were identified and quantified.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19518054     DOI: 10.1021/ac900468j

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  7 in total

1.  Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.

Authors:  Hongwei Xie; Asish Chakraborty; Joomi Ahn; Ying Qing Yu; Deepalakshmi P Dakshinamoorthy; Martin Gilar; Weibin Chen; St John Skilton; Jeffery R Mazzeo
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

2.  Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cells.

Authors:  Yantao Li; Tuo Fu; Tao Liu; Huaizu Guo; Qingcheng Guo; Jin Xu; Dapeng Zhang; Weizhu Qian; Jianxin Dai; Bohua Li; Yajun Guo; Sheng Hou; Hao Wang
Journal:  MAbs       Date:  2016-04-06       Impact factor: 5.857

3.  Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.

Authors:  Lei Zhu; Qingcheng Guo; Huaizu Guo; Tao Liu; Yingxin Zheng; Peiming Gu; Xi Chen; Hao Wang; Sheng Hou; Yajun Guo
Journal:  MAbs       Date:  2014       Impact factor: 5.857

4.  Proteome wide reduction in AGE modification in streptozotocin induced diabetic mice by hydralazine mediated transglycation.

Authors:  Suresh K Kesavan; Shweta Bhat; Sandeep B Golegaonkar; Mashanipalya G Jagadeeshaprasad; Arati B Deshmukh; Harshal S Patil; Santosh D Bhosale; Mahemud L Shaikh; Hirekodathakallu V Thulasiram; Ramanamurthy Boppana; Mahesh J Kulkarni
Journal:  Sci Rep       Date:  2013-10-15       Impact factor: 4.379

5.  Rifampicin reduces advanced glycation end products and activates DAF-16 to increase lifespan in Caenorhabditis elegans.

Authors:  Sandeep Golegaonkar; Syed S Tabrez; Awadhesh Pandit; Shalini Sethurathinam; Mashanipalya G Jagadeeshaprasad; Sneha Bansode; Srinivasa-Gopalan Sampathkumar; Mahesh J Kulkarni; Arnab Mukhopadhyay
Journal:  Aging Cell       Date:  2015-02-26       Impact factor: 9.304

6.  LC-MS characterization and purity assessment of a prototype bispecific antibody.

Authors:  R Jeremy Woods; Michael Hongwei Xie; Thomas Spreter Von Kreudenstein; Gordon Y K Ng; Surjit B Dixit
Journal:  MAbs       Date:  2013-06-24       Impact factor: 5.857

7.  Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling.

Authors:  Zhigang Wu; Peng Zhou; Xiaoxin Li; Hui Wang; Delun Luo; Huaiyao Qiao; Xiao Ke; Jian Huang
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.